Loading...

Biovica extends patent protection on key markets

Uppsala, Sweden May 9 2017. Biovica has received a new patent in China as well as patent extension for the company's technology in the United States. Both of the patents refer to Biovica's method of measuring thymidine kinase activity on a real-time PCR platform. The Chinese patent is valid until 13 May 2031. The U.S. patent [...]

2017-05-09T13:41:06+00:00 May 9th, 2017 10:00|News|

Biovica participates at ASCO, June 2-6, Chicago

Biovica will attend the ASCO (American Society of Clinical Oncology) Annual Meeting, an event that brings together 30 000 global oncology professionals. During ASCO Biovica will meet Pharma companies and oncologists to share the latest insights from the ongoing clinical trial programme and collaborations. Biovica has also been invited to present the latest DiviTum® data at [...]

2017-05-02T09:35:13+00:00 May 2nd, 2017 09:35|News|

Biovica presents at Unicorn Summit 2017

Anders Rylander, CEO will present at the Vator Securities Unicorn Summit in Stockholm on March 7, 2017. The presentation, part of the company’s planned IPO on Nasdaq First North in March 2017, is intended for investors. The purpose of the IPO is to raise funds to initiate the commercialization phase of the company’s DiviTum™ [...]

2017-03-02T09:49:27+00:00 February 23rd, 2017 15:00|News|